X4 Pharmaceuticals Management
Management criteria checks 3/4
X4 Pharmaceuticals' CEO is Paula Ragan, appointed in Jul 2014, has a tenure of 10.83 years. total yearly compensation is $2.04M, comprised of 30.3% salary and 69.7% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth €103.15K. The average tenure of the management team and the board of directors is 3.7 years and 6.2 years respectively.
Key information
Paula Ragan
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 30.32% |
| CEO tenure | 10.8yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.7yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$15m |
| Dec 31 2024 | n/a | n/a | -US$37m |
| Sep 30 2024 | n/a | n/a | -US$17m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$2m | US$620k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$111m |
| Jun 30 2023 | n/a | n/a | -US$131m |
| Mar 31 2023 | n/a | n/a | -US$96m |
| Dec 31 2022 | US$4m | US$583k | -US$96m |
| Sep 30 2022 | n/a | n/a | -US$103m |
| Jun 30 2022 | n/a | n/a | -US$102m |
| Mar 31 2022 | n/a | n/a | -US$100m |
| Dec 31 2021 | US$2m | US$562k | -US$103m |
| Sep 30 2021 | n/a | n/a | -US$85m |
| Jun 30 2021 | n/a | n/a | -US$82m |
| Mar 31 2021 | n/a | n/a | -US$78m |
| Dec 31 2020 | US$3m | US$543k | -US$62m |
| Sep 30 2020 | n/a | n/a | -US$55m |
| Jun 30 2020 | n/a | n/a | -US$55m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$2m | US$492k | -US$53m |
| Sep 30 2019 | n/a | n/a | -US$55m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$40m |
| Dec 31 2018 | US$921k | US$380k | -US$36m |
Compensation vs Market: Paula's total compensation ($USD2.04M) is above average for companies of similar size in the German market ($USD493.82K).
Compensation vs Earnings: Paula's compensation has been consistent with company performance over the past year.
CEO
Paula Ragan (54 yo)
Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.8yrs | no data | 0.63% € 103.2k | |
| CFO, Treasurer & Corporate Secretary | 6.7yrs | US$1.31m | 0% € 0 | |
| Chief Commercial Officer | 2.5yrs | US$1.17m | 0.44% € 72.1k | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder & Member of Corporate Advisory Board | no data | no data | no data | |
| Chief Operating Officer | 3.7yrs | US$1.84m | 0.28% € 46.6k | |
| VP, General Counsel & Compliance Officer | 1.7yrs | no data | no data | |
| Chief Medical Officer | 1.8yrs | US$1.64m | 0.50% € 82.0k | |
| VP of Finance & Corporate Controller | 5.7yrs | no data | no data |
Experienced Management: 48Q0's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.8yrs | no data | 0.63% € 103.2k | |
| Founder & Member of Corporate Advisory Board | 9.1yrs | no data | no data | |
| Independent Chairman of the Board | 6.8yrs | US$136.80k | 0.044% € 7.3k | |
| Independent Director | 6.2yrs | US$104.80k | 0.030% € 4.9k | |
| Independent Director | 7.7yrs | US$111.80k | 0.030% € 4.9k | |
| Independent Director | 4.6yrs | US$96.80k | 0.030% € 4.9k | |
| Independent Director | 5.7yrs | US$102.80k | 0.030% € 4.9k | |
| Member of Corporate Advisory Board | 9.1yrs | no data | no data | |
| Independent Director | 1.6yrs | US$98.80k | 0.017% € 2.8k | |
| Director | 6.2yrs | US$117.51k | 0.084% € 13.9k | |
| Independent Director | 3.6yrs | US$104.80k | 0.030% € 4.9k |
Experienced Board: 48Q0's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 11:13 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |